Search
Valneva SE
VALNAdd to Watchlist
5.225USD
+0.135+2.65%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
453.93MMarket Cap
LossP/E TTM
More Details of Valneva SE Company
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE Info
Ticker SymbolVALN
Company nameValneva SE
IPO dateJun 28, 2007
CEOLingelbach (Thomas)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJun 28
Address6, Rue Alain Bombard
CitySAINT-HERBLAIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code44800
Phone33228073710
Websitehttps://valneva.com/
Ticker SymbolVALN
IPO dateJun 28, 2007
CEOLingelbach (Thomas)
Company Executives of Valneva SE
Name
Name/Position
Position
Shareholding
Change
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
FAQs
Who are the top five shareholders of Valneva SE?
The top five shareholders of Valneva SE are: Mr. Franck Grimaud
How many institutions hold shares of Valneva SE (VALN)?
As of 2026Q1, 36 institutions hold shares of Valneva SE, with a combined market value of approximately 5.21M, accounting for 5.50% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -309162.00.
What is the biggest source of revenue for Valneva SE?
In 2026Q1, the IXIARO business generated the highest revenue for Valneva SE, amounting to 98.42M and accounting for 56.35% of total revenue.